Cargando…
Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome
Objective. Polycystic ovary syndrome (PCOS) is associated with obesity and insulin resistance (IR), key features of nonalcoholic steatohepatitis (NASH). Cytokeratin 18 fragments (M30) have been established as a serum marker for NASH. The insulin sensitizer metformin improves hepatic IR. This study e...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383456/ https://www.ncbi.nlm.nih.gov/pubmed/25873949 http://dx.doi.org/10.1155/2015/254169 |
_version_ | 1782364738629402624 |
---|---|
author | Tan, Susanne Vollmar, Nils Benson, Sven Sowa, Jan-Peter Bechmann, Lars P. Gerken, Guido Fuhrer, Dagmar Canbay, Ali |
author_facet | Tan, Susanne Vollmar, Nils Benson, Sven Sowa, Jan-Peter Bechmann, Lars P. Gerken, Guido Fuhrer, Dagmar Canbay, Ali |
author_sort | Tan, Susanne |
collection | PubMed |
description | Objective. Polycystic ovary syndrome (PCOS) is associated with obesity and insulin resistance (IR), key features of nonalcoholic steatohepatitis (NASH). Cytokeratin 18 fragments (M30) have been established as a serum marker for NASH. The insulin sensitizer metformin improves hepatic IR. This study evaluates the influence of MF on serologic NASH (sNASH) in patients with PCOS. Patients and Methods. In 89 patients, metabolic parameters, liver injury indicating fatty liver (LIFL), and M30 were assessed at baseline and after metformin treatment. Patients with initial IR were subdivided into dissolved (PCOS-exIR) and persistent IR (PCOS-PIR) after treatment and compared to an initially insulin sensitive PCOS group (PCOS-C). Results. Improvement of LIFL prevalence could be seen in PCOS-C and PCOS-exIR compared to PCOS-PIR (−19.4, resp., −12.0% versus 7.2%, Chi(2) = 29.5, P < 0.001) without change in sNASH prevalence. In PCOS-PIR, ALT levels increased significantly accompanied by a nominal, nonsignificant M30 increase. Conclusions. Metformin improves LIFL in subgroups of patients with PCOS without influencing sNASH. This could either indicate a missing effect of metformin on NAFLD or slowed disease progression. Further studies are needed to elucidate NAFLD in the context of PCOS and potential therapeutic options. |
format | Online Article Text |
id | pubmed-4383456 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-43834562015-04-13 Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome Tan, Susanne Vollmar, Nils Benson, Sven Sowa, Jan-Peter Bechmann, Lars P. Gerken, Guido Fuhrer, Dagmar Canbay, Ali Int J Endocrinol Clinical Study Objective. Polycystic ovary syndrome (PCOS) is associated with obesity and insulin resistance (IR), key features of nonalcoholic steatohepatitis (NASH). Cytokeratin 18 fragments (M30) have been established as a serum marker for NASH. The insulin sensitizer metformin improves hepatic IR. This study evaluates the influence of MF on serologic NASH (sNASH) in patients with PCOS. Patients and Methods. In 89 patients, metabolic parameters, liver injury indicating fatty liver (LIFL), and M30 were assessed at baseline and after metformin treatment. Patients with initial IR were subdivided into dissolved (PCOS-exIR) and persistent IR (PCOS-PIR) after treatment and compared to an initially insulin sensitive PCOS group (PCOS-C). Results. Improvement of LIFL prevalence could be seen in PCOS-C and PCOS-exIR compared to PCOS-PIR (−19.4, resp., −12.0% versus 7.2%, Chi(2) = 29.5, P < 0.001) without change in sNASH prevalence. In PCOS-PIR, ALT levels increased significantly accompanied by a nominal, nonsignificant M30 increase. Conclusions. Metformin improves LIFL in subgroups of patients with PCOS without influencing sNASH. This could either indicate a missing effect of metformin on NAFLD or slowed disease progression. Further studies are needed to elucidate NAFLD in the context of PCOS and potential therapeutic options. Hindawi Publishing Corporation 2015 2015-03-19 /pmc/articles/PMC4383456/ /pubmed/25873949 http://dx.doi.org/10.1155/2015/254169 Text en Copyright © 2015 Susanne Tan et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Tan, Susanne Vollmar, Nils Benson, Sven Sowa, Jan-Peter Bechmann, Lars P. Gerken, Guido Fuhrer, Dagmar Canbay, Ali Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome |
title | Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome |
title_full | Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome |
title_fullStr | Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome |
title_full_unstemmed | Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome |
title_short | Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome |
title_sort | liver injury indicating fatty liver but not serologic nash marker improves under metformin treatment in polycystic ovary syndrome |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383456/ https://www.ncbi.nlm.nih.gov/pubmed/25873949 http://dx.doi.org/10.1155/2015/254169 |
work_keys_str_mv | AT tansusanne liverinjuryindicatingfattyliverbutnotserologicnashmarkerimprovesundermetformintreatmentinpolycysticovarysyndrome AT vollmarnils liverinjuryindicatingfattyliverbutnotserologicnashmarkerimprovesundermetformintreatmentinpolycysticovarysyndrome AT bensonsven liverinjuryindicatingfattyliverbutnotserologicnashmarkerimprovesundermetformintreatmentinpolycysticovarysyndrome AT sowajanpeter liverinjuryindicatingfattyliverbutnotserologicnashmarkerimprovesundermetformintreatmentinpolycysticovarysyndrome AT bechmannlarsp liverinjuryindicatingfattyliverbutnotserologicnashmarkerimprovesundermetformintreatmentinpolycysticovarysyndrome AT gerkenguido liverinjuryindicatingfattyliverbutnotserologicnashmarkerimprovesundermetformintreatmentinpolycysticovarysyndrome AT fuhrerdagmar liverinjuryindicatingfattyliverbutnotserologicnashmarkerimprovesundermetformintreatmentinpolycysticovarysyndrome AT canbayali liverinjuryindicatingfattyliverbutnotserologicnashmarkerimprovesundermetformintreatmentinpolycysticovarysyndrome |